Skip to main content

Table 1 Correlation analysis between clinical characteristics and MATH values in the TCGA-BLCA project

From: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

Characteristics Number of patients Percent (%) MATH ± SD p value
Age, median (IQR) 408 (34–90)    p = 0.388
 ≤ 50 25 6.1 41.5 ± 19  
 51–74 254 61.3 46.1 ± 16  
 ≥ 75 133 32.6 46.5 ± 13  
Gender     p = 0.527
 Male 304 73.8 46.2 ± 16  
 Female 108 26.2 45.2 ± 13  
Race     p = 0.484
 Asian 44 11.2 43.3 ± 19  
 Caucasian 327 83.0 46.0 ± 14  
 African 23 5.8 45.6 ± 16  
 Unkown 18 Unkown Unkown  
Histologic subtype     p = 0.162
 Papillary 134 32.8 44.4 ± 18  
 Non-papillary 274 67.2 46.7 ± 14  
 Unkown 5 Unkown Unkown  
Stage     p = 0.425
 Stage I 2 0.5 49.5 ± 50  
 Stage II 131 32.0 44.3 ± 16  
 Stage III 141 34.4 45.6 ± 15  
 Stage IV 136 33.2 47.4 ± 13  
 Unkown 2 Unkown Unkown  
Grade     p = 0.024
 High-grade 388 94.9 46.2 ± 15  
 Low-grade 21 5.1 38.6 ± 18  
 Unkown 3 \   
Recurrence     p = 0.389
 Recur 147 45.1 46.8 ± 15  
 Free 179 54.9 45.3 ± 16  
 Unkown 86 Unkown Unkown